CytoMed Therapeutics is a biotechnology company incorporated in 2018 as a spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR). The company focuses on engineering more affordable cellular immunotherapies designed to identify and attack a broad range of solid and blood cancers. Its research and development centers on “off-the-shelf” allogeneic cell-based treatments, including gamma delta (γδ) T-cell and natural killer (NK)-cell approaches.

CytoMed’s platforms include iPSC-γδ NKT cell technology, called gdNKT Therapy, and CAR-γδ T-cell technology, called CTM-N2D Therapy. The company also generates induced pluripotent stem cells (iPSCs) and develops them into cellular therapeutics for customers using its proprietary technologies. Its website presents research publications spanning cellular cancer therapy, stem cells, CAR-engineered immune cells, and related immunotherapy methods.

CytoMed operates in Singapore and Malaysia, with a registered office in Singapore and a head office and GMP facility in Johor Bahru. Its work brings together stem-cell research and immune-cell engineering to advance potential cellular treatments for cancer